A 6‐month, open‐label study of memantine in patients with frontotemporal dementia

J. Diehl-Schmid,Hans Förstl,R. Perneczky,C. Pohl,A. Kurz
DOI: https://doi.org/10.1002/gps.1973
2008-07-01
International Journal of Geriatric Psychiatry
Abstract:To evaluate safety and effects on cognition and behavior of memantine 20 mg/day in the treatment of patients with frontotemporal dementia (FTD).
What problem does this paper attempt to address?